Exosomes · Lesson 11 of 18 · 3 min

Exosomes for osteoarthritis and musculoskeletal conditions: what the research shows

Why exosomes are being studied in joints, bone, tendon, muscle and spine, and why all musculoskeletal use remains investigational.

A gloved hand pipetting into small vials on a lab bench

Key takeaways.

  • Musculoskeletal tissues such as cartilage and tendon heal poorly, which is why they attract regenerative research.
  • Osteoarthritis is the most studied musculoskeletal target for exosomes.
  • Research also covers bone healing, tendon and ligament repair, muscle and intervertebral disc disease.
  • Much of the supporting evidence is preclinical, from laboratory and animal models.
  • Researchers expect earlier-stage disease, where tissue remains, to be the more plausible setting.
  • Exosomes are not FDA-approved for any musculoskeletal use.

Why musculoskeletal tissue is a research target

Several musculoskeletal tissues repair themselves poorly. Articular cartilage has no blood supply and shows almost no capacity for spontaneous healing. Tendons and ligaments heal slowly and often form disorganized scar tissue.

Bone usually heals well, but the course material notes that 5 to 10 percent of fractures progress to delayed union or non-union. Muscle regenerates after minor injury but struggles after severe loss of tissue.

Osteoarthritis

Osteoarthritis affects over 300 million people worldwide. Current care is largely symptomatic relief followed, for some patients, by joint replacement. That gap is the rationale for studying exosomes in joints.

The proposed mechanisms are the ones described for exosomes generally: reducing inflammation in the joint and supporting the cells that maintain cartilage. These are research hypotheses. Evidence in patients is limited.

Bone, tendon, muscle and spine

In bone, research looks at whether exosomes can support the normal fracture healing program when it stalls. In tendon, the interest comes from the tissue's poor blood supply and low metabolic activity, which limit natural repair.

In the spine, studies focus on intervertebral disc degeneration, where the disc's core loses hydration and its cell population declines. Muscle research focuses on settings where normal regeneration fails.

Where this stands

All musculoskeletal use of exosomes is investigational. Exosome therapies are not FDA-approved for therapeutic use.

Early experience and preclinical reasoning suggest that early-to-moderate disease, where tissue is still present, is a more plausible setting than end-stage disease. Definitive selection criteria await more clinical data.

Educational content for healthcare professionals. Not a treatment recommendation. Exosome therapies are not FDA-approved for therapeutic use.

Exosomes: 0 of 18 lessons finished

All lessons

This guide covers the what and the why.

The how is taught live. The webinar and live training go deeper on:

  • Participant selection criteria used in musculoskeletal studies
  • Reading the preclinical and clinical studies critically
  • Protocol considerations in research settings
  • Evidence gaps by tissue type

Common questions.

Are exosomes approved for knee osteoarthritis?
No. Exosome therapies are not FDA-approved for osteoarthritis or any other therapeutic use. Use in joints is investigational.
Why is cartilage so hard to repair?
Articular cartilage lacks a blood supply, nerve supply and access to circulating stem cells, so it has almost no capacity to heal on its own once damaged.
What musculoskeletal conditions are being studied with exosomes?
Research covers osteoarthritis, fracture healing, tendon and ligament injury, muscle regeneration and intervertebral disc degeneration. Much of it is preclinical.

Sources

  • Cosenza, S., et al. (2017). Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. Theranostics, 7(9), 1437-1451.
  • Furuta, T., et al. (2016). Mesenchymal stem cell-derived exosomes promote fracture healing in a mouse model. Stem Cells Translational Medicine, 5(12), 1620-1630.
  • Shi, Z., et al. (2019). MSC-derived exosomes promote Achilles tendon healing. Stem Cells International, 2019, 5671237.

Ready for the hands-on detail?

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.